NEWPORT, Ky., July 13 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women’s healthcare and pain management, today announced the appointment of three new members to its executive management team. Joining the company are Natasha Giordano, Chief Commercial Officer; Rita O’Connor, Chief Financial & Information Officer; and Peter Wentworth, Senior Vice President, Human Resources.
Ms. Giordano has more than 25 years of experience in the healthcare and pharmaceutical industry and most recently served as President Americas at Cegedim Dendrite, a global sales and marketing solutions and information company specializing in the pharmaceutical industry. Her depth of experience includes senior leadership positions in general management, marketing, compliance, and sales at major pharmaceutical companies including Pfizer and Parke-Davis.
Mr. Wentworth has extensive experience within the field of human resources, including more than 25 years working in global healthcare and consumer products industries. Most recently he was Executive Vice President, Human Resources at Adams Respiratory Therapeutics. Wentworth is a seasoned business leader, who has held a broad range of positions at major global companies such as Pfizer, Warner-Lambert, and PepsiCo.
About Xanodyne
Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women’s healthcare and pain management. Xanodyne markets a portfolio of products consisting of FDA approved pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne’s focus areas.
Xanodyne Pharmaceuticals, Inc.
